Lead evolution in development of an anti-allergic agent; dimethyl(2-phenoxyethyl)sulfonium p-toluenesulfonate as the secondary lead compound

Abstract

Derivatives of 2-hydroxyethyldimethylsulfonium p-toluenesulfonate (1) were evaluated for anti-allergic activity in order to develop the drug for treatment of type I allergic diseases. The IgE-induced rat homologous passive cutaneous anaphylaxis (PCA) was inhibited by some 2-alkoxy and 2-aryloxyethyl sulfonium p-toluenesulfonates. There were some correlations between hydrophobicity or electronic properties (HOMO or charge at the O atom) and anti-allergic activity or acute toxicity. Dimethyl(2-phenoxyethyl)sulfonium p-toluenesulfonate (5) was selected as a second lead compound in the next stage. Copyright 2002 Chem-Bio Informatics Society.